CINECA IRIS Institutional Research Information System

ANTONIOLI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.877
AS - Asia 7.537
EU - Europa 6.761
SA - Sud America 1.179
Continente sconosciuto - Info sul continente non disponibili 797
AF - Africa 385
OC - Oceania 30
Totale 35.566
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.357
IT - Italia 2.763
SG - Singapore 2.441
CN - Cina 1.982
HK - Hong Kong 1.235
BR - Brasile 982
SE - Svezia 870
VN - Vietnam 643
DE - Germania 571
BG - Bulgaria 452
GB - Regno Unito 385
CA - Canada 325
FI - Finlandia 323
FR - Francia 292
TR - Turchia 277
RU - Federazione Russa 271
AT - Austria 256
IN - India 210
JP - Giappone 165
CI - Costa d'Avorio 148
NL - Olanda 125
UA - Ucraina 123
KR - Corea 107
MX - Messico 83
PL - Polonia 77
AR - Argentina 74
BD - Bangladesh 66
CH - Svizzera 64
IQ - Iraq 63
PK - Pakistan 62
BE - Belgio 47
SN - Senegal 46
UZ - Uzbekistan 39
ID - Indonesia 38
ZA - Sudafrica 38
NG - Nigeria 37
ES - Italia 30
VE - Venezuela 30
CO - Colombia 27
EC - Ecuador 26
IR - Iran 26
MA - Marocco 26
SA - Arabia Saudita 26
AU - Australia 24
CR - Costa Rica 24
JM - Giamaica 23
EG - Egitto 22
PH - Filippine 21
KE - Kenya 17
CZ - Repubblica Ceca 16
LT - Lituania 16
AE - Emirati Arabi Uniti 15
MY - Malesia 14
PY - Paraguay 14
AZ - Azerbaigian 13
HN - Honduras 13
TW - Taiwan 13
CL - Cile 11
DZ - Algeria 11
IE - Irlanda 11
PT - Portogallo 11
TN - Tunisia 11
AL - Albania 10
IL - Israele 10
JO - Giordania 9
LB - Libano 9
PA - Panama 9
TT - Trinidad e Tobago 9
NO - Norvegia 8
BJ - Benin 7
KZ - Kazakistan 7
OM - Oman 7
PE - Perù 7
DO - Repubblica Dominicana 6
ET - Etiopia 6
HU - Ungheria 6
KG - Kirghizistan 6
NI - Nicaragua 6
RS - Serbia 6
UY - Uruguay 6
BY - Bielorussia 5
GR - Grecia 5
NZ - Nuova Zelanda 5
PS - Palestinian Territory 5
RO - Romania 5
SV - El Salvador 5
BS - Bahamas 4
CG - Congo 4
DK - Danimarca 4
GD - Grenada 4
GH - Ghana 4
NP - Nepal 4
QA - Qatar 4
AO - Angola 3
EU - Europa 3
GE - Georgia 3
GT - Guatemala 3
LV - Lettonia 3
MO - Macao, regione amministrativa speciale della Cina 3
TH - Thailandia 3
Totale 34.741
Salva come PNG Salva come JPEG
Città #
Ashburn 1.880
Singapore 1.347
Fairfield 1.263
Hong Kong 1.194
Woodbridge 1.178
Dallas 1.045
Ann Arbor 940
San Jose 940
Houston 858
Santa Clara 811
Chandler 782
Seattle 502
Wilmington 482
Cambridge 449
Milan 447
Sofia 446
Shanghai 441
Beijing 406
Council Bluffs 391
Serra 376
New York 365
Los Angeles 283
Boardman 278
Princeton 192
Ottawa 190
Pisa 181
Vienna 174
Lawrence 168
Lauterbourg 161
Florence 159
Medford 150
Abidjan 148
Tokyo 137
Ho Chi Minh City 132
Izmir 131
Jacksonville 123
Helsinki 121
Munich 121
Hefei 118
Rome 117
Dong Ket 116
Hanoi 112
Des Moines 110
São Paulo 109
Chicago 108
London 108
Buffalo 98
Istanbul 93
Nanjing 93
Frankfurt am Main 91
Seoul 86
Atlanta 85
Bremen 81
Redondo Beach 74
Dearborn 73
Turku 57
Lucca 55
Washington 51
Lappeenranta 50
Nanchang 49
Columbus 48
Toronto 47
Warsaw 47
Dakar 46
Lancaster 46
Phoenix 46
Ogden 44
Brussels 43
San Diego 41
The Dalles 41
Redwood City 40
Falls Church 39
Montreal 39
Naples 35
Tashkent 35
Lagos 34
Orem 33
Chennai 32
Nuremberg 32
Boulder 29
Brooklyn 29
San Francisco 29
Zurich 29
Bern 28
Rio de Janeiro 28
Bologna 27
Montignoso 27
Pune 27
Guangzhou 26
Changsha 25
Livorno 24
Tianjin 24
Kunming 23
Marseille 23
Amsterdam 22
Denver 22
Fuzhou 22
Hebei 22
Porto Alegre 22
Turin 22
Totale 22.624
Salva come PNG Salva come JPEG
Nome #
Derivati isoindolici come attivatori di AMPK 545
Efficacy of Lisosan G (fermented wheat) on reactive hypoglycemia after bariatric surgery 375
Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study 374
Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity 353
Preparation of isoindoline derivatives for use as AMPK activators 351
Enteric glial NLRP3 inflammasome contributes to gut mucosal barrier alterations in a mouse model of diet-induced obesity 345
Telogen effluvium following bivalent human papilloma virus vaccine administration: a report of two cases 334
Protective effects of Saccharomyces boulardii CNCM I-745 Against Nonsteroidal anti-inflammatory drug-induced intestinal injury 312
An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. 309
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon 285
Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors, 282
Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease 279
Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment 279
Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity 279
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 276
Derivati benzofuranici come attivatori di AMPK 262
Quality of adverse drug reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance 256
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis 255
Adenosine signaling as target in cardiovascular pharmacology 254
Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia 247
Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention 240
Anti-inflammatory effect of a novel adenosine deaminase inhibitor in experimental colitis 239
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 235
Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management 234
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 234
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 228
Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations 227
Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability 225
Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors 222
Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition 222
Emerging role of Cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions 218
The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity 215
Commentary: Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling 214
A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis 213
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic 212
CD39 and CD73 in immunity and inflammation 212
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation 212
Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition 211
Anti-CD73 in cancer immunotherapy: awakening new opportunities 211
Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects 211
Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome 209
A1 and A2a receptors mediate inhibitory rffects of adenosine on the motor activity of human colon 208
Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury 205
NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity 205
Role of Cyclooxygenase isoforms in the neuromodulation of colonic motility in Humans and Mice 204
Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district 203
Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy 203
Clinical efficacy of esomeprazole in the prevention and healing of digestive toxicity associated with non-steroidal anti-inflammatory drugs in elderly patients 203
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 203
Cyclooxygenase inhibitors modulate pro-fibrotic signalling mediated by TGFbeta in experimental colitis 202
Small Intestine Neuromuscular Dysfunctions and Neurogliopathy in a Mouse Model of High-Fat Diet-Induced Obesity: Involvement of Toll-Like Receptor 4 201
Cyclooxygenase expression in neuromuscular compartment of normal and inflamed colon 200
Enteric protective effects of the combination Bifidobacterium longum and lactoferrin in a rat model of diclofenac-induced intestinal injury. 197
Neuromodulation of colonic motility by cycloxygenase isoforms in the presence of experimental bowel inflammation 196
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 196
Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity 195
Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity 194
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment 193
Role of A2a adenosine in the regulation of colonic motility in normal human colon 191
Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders 191
Adverse reactions to oncologic drugs: spontaneous reporting and signal detection 190
Oral sucrosomial iron is as effective as intravenous ferric carboxy‐maltose in treating anemia in patients with ulcerative colitis 190
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 189
The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders 189
Preparation of benzofuran derivatives for use as AMPK activators 188
Expression pattern of COX isoforms in experimental models of enteric and airway inflammation 187
Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases 187
Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab 187
Effects of esomeprazole on healing of non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: characterization of molecular mechanisms 186
Donepezil improves vascular function in a mouse model of Alzheimer's disease 186
Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation 185
Differential role of cyclooxygenase 1 and 2 isoforms in the modulation of colonic neuromuscular function in experimental inflammation 184
Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity 184
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology 184
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 183
Effects of selective cyclooxygenase-2 inhibitors on healing of experimental gastric ulcers and mucosal expression of cyclooxygenase isoforms 183
Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice 183
Reduced modulating actions of adenosine pathways on enteric neuromuscular activity in experimental colitis 182
Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction 182
Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy 181
Myeloid cells in the tumor microenvironment: Role of adenosine 179
Differential role of A1 and A2a purinergic receptors in the control of colonic neurumuscular function in the presence of experimental colitis 176
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications 176
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 176
Allopurinol adherence among patients with gout: an Italian general practice database study 176
High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse 176
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? 176
Control of enteric neuromuscular functions by purinergic A3 receptors in normal rat distal colon and experimental bowel inflammation 175
Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review 175
Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage 175
Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies 175
The intestinal barrier in disorders of the central nervous system 174
Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders 171
Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease 171
Enteric Glia and Brain Astroglia: Complex Communication in Health and Disease along the Gut-Brain Axis 170
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models 170
Adenosine and inflammation: what's new on the horizon? 167
Transient acute liver failure complicating transurethral resection syndrome 167
The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors 166
Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases 164
Totale 21.851
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.699
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.699
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.932 0 0 66 105 390 307 74 115 127 86 138 524
2022/20232.925 334 398 220 282 285 387 37 229 479 49 190 35
2023/20242.469 221 223 285 193 360 427 63 115 106 96 132 248
2024/20256.733 82 252 109 397 552 730 649 299 735 864 710 1.354
2025/20268.439 532 896 1.093 724 855 669 1.287 420 548 817 308 290
2026/20273.439 529 2.312 598 0 0 0 0 0 0 0 0 0
Totale 35.566